ClinicalTrials.gg

Program

Tadalafil

Also written as “tadalafil”, “Tadalafil 20 mg” and “Cialis Tab. 5mg”.

Its studies are mostly in Erectile Dysfunction · Prostatic Hyperplasia · Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Carcinoma, Non-Small-Cell Lung, led by 8 companies.

Furthest: phase 4, since May 31, 200659 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly490 open or runningphase 4since May 31, 2006Dec 16, 2002none ahead
Chong Kun Dang Pharmaceutical30 open or runningphase 3since Sep 2, 2015Sep 15, 2014none ahead
Pfizer20 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead
Futura Medical Developments10 open or runningphase 3since Jul 26, 2021Jul 26, 2021none ahead
Hanmi Pharmaceutical10 open or runningphase 1since Sep 4, 2014Sep 4, 2014none ahead
lidia-larran-aga10 open or runningphase 3since May 6, 2020May 6, 2020none ahead
Sanofi10 open or runningphase 3since Jan 17, 2025Jan 17, 2025none ahead
Seattle Gummy11 open or runningphase 1since Feb 17, 2021Feb 17, 2021none ahead

Also a collaborator on its studies: Bristol-Myers Squibb, Gilead Sciences, nippon-shinyaku-co-ltd and icos-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Dec 16, 2002.

  1. Apr 1, 2013Phase 3 study in Hypertension, PulmonaryEli Lilly · NCT01824290 · 35 enrolled · United States, Austria, Belgium and more
  2. May 24, 2013Phase 3 study in Muscular Dystrophy, DuchenneEli Lilly · NCT01865084 · 331 enrolled · United States, Argentina, Belgium and more
  3. Sep 4, 2013Phase 3 study in Prostatic HyperplasiaEli Lilly · NCT01937871 · 909 enrolled · China
  4. Jul 17, 2014Phase 2 study in Essential HypertensionEli Lilly · NCT02194465 · 304 enrolled · United States, Canada, Puerto Rico
  5. Aug 20, 2014Phase 4 study in Erectile DysfunctionEli Lilly · NCT02224846 · 635 enrolled · China
  6. Sep 4, 2014Hanmi Pharmaceutical's first study: phase 1 study in Erectile DysfunctionNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT02239484 · 30 enrolled · Korea, Republic of
  7. Sep 15, 2014Chong Kun Dang Pharmaceutical's first studies: 2 phase 1 studiesNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02247518, NCT02247505
  8. Nov 20, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02300259 · 48 enrolled · United States
  9. Apr 28, 2015Phase 4 study in Prostatic HyperplasiaEli Lilly · NCT02431754 · 171 enrolled · Japan
  10. Sep 2, 2015Phase 3 study in Prostatic HyperplasiaChong Kun Dang Pharmaceutical · NCT03246880 · 455 enrolled · Korea, Republic of
  11. May 6, 2020lidia-larran-aga's first study: phase 3 study in Sexual Dysfunctions, PsychologicalNew to lidia-larran-agalidia-larran-aga · NCT04433559 · 80 enrolled
  12. Feb 17, 2021Seattle Gummy's first study: phase 1 study in Erectile DysfunctionNew to Seattle GummySeattle Gummy · NCT04762082 · 30 planned
  13. Jul 26, 2021Futura Medical Developments's first study: phase 3 study in Erectile DysfunctionNew to Futura Medical DevelopmentsFutura Medical Developments · NCT04984993 · 116 enrolled · United States, Bulgaria, Georgia and more
  14. Jan 17, 2025Sanofi's first study: phase 3 study in Erectile DysfunctionNew to SanofiSanofi · NCT06805513 · 2,212 enrolled · United States

TargetBeta

PDE5A →read by rule
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule

Other programs on PDE5A

ProgramCompanyFurthest phaseStudies
sildenafilruleViatrisphase 474

Studies

All 59 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06805513Erectile Dysfunction · United States3CompletedSanofiMar 2, 20262,212
NCT04984993Erectile Dysfunction · United States, Bulgaria, Georgia and more3CompletedFutura Medical DevelopmentsJul 13, 2022116
NCT04762082Erectile Dysfunction1Not yet recruitingSeattle GummyAug 30, 202530
NCT04433559Sexual Dysfunctions, Psychological3UNKNOWNlidia-larran-agaAug 202180
NCT03246880Prostatic Hyperplasia · Korea, Republic of3CompletedChong Kun Dang PharmaceuticalApr 2016455
NCT02431754Prostatic Hyperplasia · Japan4CompletedEli LillyFeb 2016171
NCT02300259Healthy Volunteers · United States1CompletedEli LillyApr 201548
NCT02247518Healthy · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalOct 201416
NCT02247505Healty Male Volunteers · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalOct 201429
NCT02239484Erectile Dysfunction · Korea, Republic of1CompletedHanmi PharmaceuticalSep 201430
NCT02224846Erectile Dysfunction · China4CompletedEli LillyMay 2016635
NCT02194465Essential Hypertension · United States, Canada, Puerto Rico2CompletedEli LillyMar 2015304
NCT01937871Prostatic Hyperplasia · China3CompletedEli LillyDec 2015909
NCT01865084Muscular Dystrophy, Duchenne · United States, Argentina, Belgium and more3TerminatedEli LillyDec 2015331
NCT01824290Hypertension, Pulmonary · United States, Austria, Belgium and more3CompletedEli LillyMar 18, 201935
NCT01484431Pulmonary Arterial Hypertension · United States, Canada, France and more2CompletedEli LillyApr 21, 201720
NCT01460342Prostatic Hyperplasia · Japan, Korea, Republic of3CompletedEli LillyOct 2012610
NCT01352507Erectile Dysfunction · China4CompletedEli LillyJun 2012383
NCT01244620Pulmonary Arterial Hypertension · Singapore1TerminatedPfizerDec 201016
NCT01183650Prostatic Hyperplasia · Germany1CompletedEli LillyApr 201124
NCT01160289Erectile Dysfunction · United States2CompletedEli LillyNov 2011410
NCT01152190Prostatic Hyperplasia · United States, Austria, Italy3CompletedEli LillyJul 201297
NCT01139762Prostatic Hyperplasia · United States, Argentina, Belgium and more3CompletedEli LillyFeb 2012696
NCT01130532Erectile Dysfunction · United States, Canada4CompletedEli LillyJan 2012623
NCT01122264Erectile Dysfunction · France, Germany, Greece and more4CompletedEli LillyJun 2011770
NCT01026818Erectile Dysfunction · Belgium, Canada, France and more4CompletedEli LillyOct 2012583
NCT00970632Prostatic Hyperplasia · Australia, Austria, Belgium and more3CompletedEli LillyJan 2011511
NCT00861757Prostatic Hyperplasia · Japan, Taiwan3CompletedEli LillyJun 2010612
NCT00855582Erectile Dysfunction · United States, Canada, France and more3CompletedEli LillyJul 2010606
NCT00848081Prostatic Hyperplasia · United States, Puerto Rico3CompletedEli LillyDec 2009318
NCT00836693Erectile Dysfunction · Germany, Greece, Italy and more3CompletedEli LillyJan 2010217
NCT00833638Erectile Dysfunction · United States4CompletedEli LillyJun 2009372
NCT00827242Prostatic Hyperplasia · United States, Argentina, Germany and more3CompletedEli LillyNov 2009325
NCT00783094Prostatic Hyperplasia · Japan2CompletedEli LillyJun 2009422
NCT00734604Erectile Dysfunction · United States, Australia, Brazil and more3CompletedEli LillySep 2009378
NCT00549302Hypertension, Pulmonary · United States, Belgium, Canada and more3CompletedEli LillyFeb 2012357
NCT00547625Prostatic Hyperplasia · United States2CompletedEli Lilly275
NCT00547599Erectile Dysfunction · Sweden4CompletedEli Lilly659
NCT00547573Erectile Dysfunction · China3CompletedEli Lilly367
NCT00547508Erectile Dysfunction · United States3CompletedEli Lilly485
NCT00547495Erectile Dysfunction · Japan3CompletedEli Lilly343
NCT00547417Erectile Dysfunction · United States3CompletedEli Lilly1,933
NCT00547352Erectile Dysfunction · Korea, Republic of4CompletedEli Lilly160
NCT00547287Erectile Dysfunction · Brazil3CompletedEli Lilly2,760
NCT00547183Erectile Dysfunction · Germany3CompletedEli Lilly298
NCT00547092Erectile Dysfunction · United Kingdom4CompletedEli Lilly386
NCT00540124Prostatic Hyperplasia · Korea, Republic of2CompletedEli LillyJun 2008151
NCT00422734Erectile Dysfunction · United States, Austria, France and more3CompletedEli LillyJan 2008342
NCT00422578Erectile Dysfunction · Finland4CompletedEli Lilly200
NCT00421083Erectile Dysfunction · United States3CompletedEli Lilly180
NCT00386009Prostatic Hyperplasia · United States, Greece, Portugal2CompletedEli LillyMay 2008200
NCT00384930Prostatic Hyperplasia · United States3CompletedEli LillyOct 20071,058
NCT00382135Erectile Dysfunction · United States4CompletedEli Lilly282
NCT00381732Erectile Dysfunction · United States3CompletedEli Lilly280
NCT00333281Erectile Dysfunction · United States4CompletedEli Lilly198
NCT00174486Erectile Dysfunction2CompletedPfizer300
NCT00157326Hypertension · United States2CompletedEli Lilly180
NCT00125918Hypertension, Pulmonary · United States, France, Italy3CompletedEli LillyAug 2007406
NCT00050609Gastroparesis · Canada2CompletedEli Lilly2

How it is read

Names in the registry

  • “tadalafil”, 45 entries
  • “Tadalafil”, 25 entries
  • “Tadalafil 20 mg”, 2 entries
  • “Cialis Tab. 5mg”, 2 entries
  • “Tadalafil 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.